title: Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
abstract: In this study we evaluated the efficacy of an L-asparaginase-based LOP (L-asparaginase, vincristine, and dexamethasone) regimen in extranodal Natural Killer (NK)/T-cell lymphoma (ENKTL) patients in the Guizhou province of China.
  
  
  
  Forty-eight patients were treated with the LOP (L-asparaginase, vincristine and dexamethasone) regimen chemotherapy (CT) and 32 patients with the CHOP (cyclophosphamide, tetrahydropyanyl adriamycin, vincristine, and prednisone) regimen. These patients then received involved-field radiotherapy (RT) with the doses of DT = 49-59 Gy.
  
  
  
  A significant improvement of clinical end points with the LOP regimen was noticed compared with the CHOP regimen: 33 (68.8%) versus 16 (50.0%) for complete responses; 10 (20.8%) versus 5 (15.6%) for partial responses. There were statistical differences in objective response rates (43 [89.6%] for LOP vs. 21 [65.6%] for CHOP; P = .009), 3 years of overall survival (42 [87.5%] for LOP vs. 20 [62.5%] for CHOP; P = .006) and progression-free survival (32 [79.2%] for LOP vs. 16 [50.0%] for CHOP; P = .007).
  
  
  
  The results showed that the LOP regimen is safe and much more efficient than the CHOP regimen for stage IIE ENKTL patients. They indicate that the LOP regimen is a satisfying alternative protocol among the other L-asparaginase-based regimens reported so far, such as SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide), GELOX (gemcitabine, oxaliplatin, and L-asparaginase), CHOP-L, and sandwich (CT, then RT, then CT).
authors.affiliation: Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
authors.forename: Limin
authors.initials: L
authors.lastname: Huang
authors.affiliation: Department of Hematology, Guizhou Cancer Hospital, Guiyang, Guizhou, China. Electronic address: xgiyb@sina.com.
authors.forename: Bin
authors.initials: B
authors.lastname: Yuan
authors.affiliation: Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
authors.forename: Haixia
authors.initials: H
authors.lastname: Wu
authors.affiliation: Department of Hematology, Guizhou Cancer Hospital, Guiyang, Guizhou, China.
authors.forename: Hongliang
authors.initials: H
authors.lastname: Chu
authors.affiliation: Department of Hematology, Guizhou Cancer Hospital, Guiyang, Guizhou, China.
authors.forename: Yayun
authors.initials: Y
authors.lastname: Liu
authors.affiliation: INSERM UMR_S 1165/Paris 7, Hôpital Saint Louis, Paris, France.
authors.forename: Shuang
authors.initials: S
authors.lastname: Wu
authors.affiliation: INSERM UMR_S 1165/Paris 7, Hôpital Saint Louis, Paris, France.
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.affiliation: INSERM UMR_S 1165/Paris 7, Hôpital Saint Louis, Paris, France. Electronic address: he.lu@inserm.fr.
authors.forename: He
authors.initials: H
authors.lastname: Lu
authors.affiliation: Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China. Electronic address: 1728436708@qq.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D002681:China; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D001215:Asparaginase; D011241:Prednisone
keywords: Chemotherapy; L-asparaginase; Lymphoma; Radiotherapy